Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-helper lymphocytes (Th cells), also known as CD4+ T cells, are a critical component of the adaptive immune system. They express the surface protein CD4 and recognize antigens presented by MHC class II molecules on antigen-presenting cells (APCs). Th cells are essential for coordinating almost all adaptive immune responses by activating other immune cells, including B cells, cytotoxic T cells, and macrophages, through cytokine release and direct cell interactions. They differentiate into various subtypes (Th1, Th2, Th17, Tfh, Treg) depending on the cytokine environment during activation, allowing for tailored responses against different pathogens or for immune regulation. Their function is crucial in defending against infectious diseases, but their dysregulation is implicated in autoimmune diseases and allergies. HIV primarily targets these cells, leading to severe immunodeficiency. Modulating T-helper cell responses is an important strategy in developing therapies for various immunological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-helper lymphocytes (Th cells).